University of Melbourne and Clarity Pharmaceuticals partnership progresses following assignment of key patents

Illustration of tumour cell with drug attached — The technology allows improved targeting of radiopharmaceuticals to tumour cells. Image credit: Clarity Pharmaceuticals

The University of Melbourne has assigned a patent portfolio for radiopharmaceutical technologies to Clarity Pharmaceuticals, a clinical stage radiopharmaceutical company focused on the treatment of serious disease.

The assignment provides Clarity with the full rights and ownership of the patents moving forward.

“The University of Melbourne has been one of the main collaborating institutions with Clarity on many levels, including basic research, early pre-clinical development, intellectual property, grant funding and direct investment,” Clarity’s Executive Chairman Dr Alan Taylor said.

“The research of Professor Paul Donnelly and his team at the School of Chemistry and Bio21 Institute of Molecular Science and Biotechnology, University of Melbourne, has been critical to the successful development and commercialisation of Clarity’s platform SAR Technology.”

Dean of Science Professor Moira O’Bryan said: “Our collaboration with Clarity has seen significant benefits already to both organisations, and we look forward to our continued relationship with the Company as it progresses its very exciting ambitions of treating childhood cancer as well as other large cancer indications such as prostate and breast cancers.”

For more details, read the full media release from Clarity Pharmaceuticals.